Onconova Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Onconova Therapeutics, Inc. - overview
Established
1998
Location
-, PA, US
Primary Industry
Biotechnology
About
Onconova Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapies for cancer treatment, leveraging novel drug discovery and development approaches. Onconova Therapeutics, Inc. specializes in oncology therapeutics and was founded in 1998.
The company is headquartered in Newtown, Pennsylvania, USA. Steven Fruchtman leads the organization as CEO. Onconova has successfully raised a total of USD 21. 00 mn through its most recent funding round, a Private Placement/Follow on that closed in September 2021.
This funding supports the company’s ongoing research and operational efforts, highlighting its strategic focus on advancing cancer therapies. Onconova Therapeutics develops a range of innovative cancer treatment products designed to meet specific therapeutic needs. Their offerings include proprietary drug candidates aimed at various malignancies, focusing on improving patient outcomes. The company collaborates with healthcare providers and research institutions across North America, Europe, and Asia, ensuring their solutions address diverse clinical challenges in oncology.
In the year 2022, Onconova Therapeutics reported a revenue of USD 226,000 and an EBITDA of USD -19,613,000, reflecting their early-stage operational status in the biotechnology sector. Onconova Therapeutics plans to utilize the USD 21. 00 mn raised in September 2021 for working capital and general corporate purposes, allowing them to enhance their research and development efforts for new oncology products. The company aims to expand its reach into European and Asian markets by 2023, increasing availability and collaborations with international healthcare providers.
Continued investment in clinical trials and the development of innovative therapies is central to their growth strategy.
Current Investors
Lincoln Park Capital, ICICI Venture, Riverstone Holdings
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.onconova.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Onconova Therapeutics, Inc. - timeline of key events
Onconova Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.